On November 7, 2023, the company's metoclopramide hydrochloride injection was accepted by the State Food and Drug Administration.

Metoclopramide Hydrochloride Injection is a gastrointestinal motility enhancer and is often used clinically as an antiemetic. It can be used for vomiting caused by chemotherapy, radiotherapy, surgery, craniocerebral injury, brain trauma sequelae, sea and air operations, and drugs; it can also be used for the symptomatic treatment of nausea and vomiting symptoms in various diseases such as acute gastroenteritis, biliary pancreas, and uremia. ; It can also be used before diagnostic duodenal intubation to facilitate smooth intubation; gastrointestinal barium X-ray examination can reduce nausea and vomiting reactions and promote the passage of barium.

Metoclopramide is an old variety that was launched in the 1960s, with wide clinical applications and a long product life cycle. The company has also deployed APIs and injections, and plans to cultivate this variety to become one of the company's strategic products.

Genchain's early product portfolio mainly revolves around the new national drug reform policy. It is expected that nearly 30 of the company's more than 40 projects are expected to catch up with the country's first batch of centralized procurement. Through centralized procurement, Genchain can become one of the main supplier with a large share of my country's medical institutions market in the next five years. In order to achieve sustainable development, the company is currently planning to introduce international elements. On the one hand, it will graft international resources in raw material procurement, research and development and other aspects, enter the field of complex generic drug development, and selectively intervene in the blue ocean track. On the one hand, it explores the licensing introduction path, introduces innovative drugs from Europe and other regions in a timely manner, and uses a differentiated strategy to enhance Genchain's competitiveness in the domestic pharmaceutical market. At the same time, relying on Hainan's location advantages and free trade zone policy support, we are targeting international markets such as Southeast Asia and Europe in product development and design, product clinical layout, production system and quality system construction, market expansion, etc., becoming a globally competitive industry. and brand reputation of pharmaceutical companies.